Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review

ABSTRACT Anemia is the most common complication of end‐stage renal disease (ESRD). While erythropoiesis‐stimulating agents (ESA) have improved treatment outcomes, some patients exhibit intolerance or hyporesponsiveness. Roxadustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI), i...

Full description

Bibliographic Details

Published in:	Clinical Case Reports
Main Authors:	Meng Zhang, Yanchao Guo, Yan Zhu, Juan Yang
Format:	Article
Language:	English
Published:	Wiley 2025-10-01
Subjects:	adolescent anemia prolyl‐hydroxylase inhibitors renal dialysis Roxadustat
Online Access:	https://doi.org/10.1002/ccr3.70985